首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1410027

數位生物標記市場 – 2023 年至 2028 年預測

Digital Biomarkers Market - Forecasts from 2023 to 2028

出版日期: 2023年12月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

數位生物標記市場預計在預測期內將以 9.22% 的複合年成長率成長。

穿戴式裝置、行動健康應用程式和遠端患者監護解決方案的出現放大了數位生物標記市場的成長。這些技術提供的對生命徵象、活動量、睡眠模式和其他健康相關因素的連續、非侵入性監測會產生大量資料，可以對這些數據進行分析以提供有用的見解。隨著醫療保健產業擁抱數位轉型，數位生物標記的市場規模預計將大幅擴大。先進分析、人工智慧和機器學習演算法的應用將增加數位生物標記的價值和可用性。這為疾病預防、個體化治療和改善患者治療結果帶來了新的機會。

市場促進因素：

穿戴式裝置和行動健康應用程式的採用率增加：

隨著穿戴式裝置和行動健康應用程式的日益普及，數位生物標記市場正在向前發展。使用者可以利用這些技術測量生命徵象，收集各種健康指標的資料，並以易於使用的方式了解自己的健康狀況。隨著穿戴式裝置和行動應用程式的普及，現在可以以更個人化和精確的方式創建和使用數位生物標記。

遠端患者監護方案的需求量很大：

由於對遠端患者監護方案的需求不斷增加，數位生物標記市場正在顯著擴大。遠端患者監護可讓醫療保健專業人員遠端監控患者健康狀況、收集即時資料並識別潛在問題。這項需求是由提供高效且具成本效益的醫療保健的需求所驅動的，特別是對於慢性病患者和需要持續監測的患者。

醫療保健組織和技術公司之間的合作和聯盟：

由於科技公司和醫療機構之間的大量合作，數位生物標記市場預計將出現積極成長。這些將臨床專業知識與技術進步相結合的合作使得數位生物標記在醫療保健環境中的成功創新解決方案和應用成為可能。

擴展數位基礎設施和連接：

擴大數位生物標記市場需要擴大數位基礎設施和連接。隨著網際網路的普及、通訊的進步以及 5G 網路的引入，數位生物標記現在可以無縫整合到醫療保健系統中。所有這些因素都在增加資料收集、儲存和分析的機會。

預計北美將佔據主要市場佔有率。

由於該地區先進的醫療基礎設施和對數位醫療技術的大量投資，預計北美將佔據重要的市場佔有率。此外，該地區大型製藥企業的存在促進了數位生物標記物開發的合作和創新。此外，數位生物標記市場的成長受到有利的政府舉措和政策的推動。最後，北美數位生物標記市場佔有率得到了穿戴式裝置、行動健康應用和遠端患者監護解決方案的快速普及的支持。

數位生物標記市場的主要企業

Biofourmis：一個名為 Biofourmis 的綜合數位治療平台，利用穿戴式科技和人工智慧來收集和分析患者產生的健康資料。我們為慢性病管理和急性後護理提供個人化見解、預測分析和遠端監控等選項。
Evidation Health：一家透過分析數位設備的真實資料來創建和檢驗數位生物標記的公司。該公司使用的技術收集和分析來自各種來源的資料，從而能夠為多種疾病創建和評估新的生物標記。
Empatica： Empatica 的智慧型手錶和腕帶是測量各種生理特徵的穿戴式設備的範例。從設備收集的心率、皮膚電活動和活動水平資料可以找到壓力和癲癇等疾病的數位生物標記。

主要進展：

2023 年 3 月，中外製藥株式會社與技術支援護理服務領域的全球領導者 Biofourmis 簽訂了一項持續協議，將開發數位技術以客觀評估子宮內膜異位症患者的疼痛。一項關於研究和實用化的新合作協議被宣布。 10%的育齡女性患有子宮內膜異位症，其中70%患有慢性骨盆腔不適，影響生活品質。 2023 年 1 月，杜克大學 BIG IDEAs 實驗室與 Evidation 建立了合作夥伴關係，透過建立在日常生活中提供更好的健康分析的分析結構來增加數位健康研究的多樣性和包容性。

The digital biomarkers market growth is expanding as wearable devices, mobile health applications, and solutions for remote patient monitoring emerge. Continuous, non-invasive monitoring of vital signs, activity levels, sleep patterns, and other health-related factors is provided by these technologies, which generate a wealth of data that can be analyzed to provide useful insights. As the healthcare industry embraces digital transformation, it is anticipated that the digital biomarkers market size will expand significantly. Digital biomarkers' value and usability will rise as a result of the application of advanced analytics, AI, and machine learning algorithms. This will open up new opportunities for disease prevention, individualized treatment, and improved patient outcomes.

Market Drivers:

Increasing Adoption of Wearable Devices and Mobile Health Applications:

The digital biomarkers market is moving forward as wearable devices and mobile health apps are becoming more and more popular. Users can use these technologies to measure vital signs, collect data on a variety of health metrics, and keep track of their health in an easy-to-use manner. Digital biomarkers can now be created and used in a more personalized and precise manner thanks to the growing use of wearables and mobile applications.

Remote Patient Monitoring Solutions are in High Demand:

The digital biomarkers market is experiencing significant expansion as a result of the rising demand for remote patient monitoring solutions. Healthcare professionals can remotely monitor their patient's health status, collect real-time data, and identify potential issues with remote patient monitoring. This demand is being driven by the need for healthcare delivery that is both efficient and cost-effective, particularly for patients who have chronic conditions or who require continuous monitoring.

Collaborations and alliances between healthcare organizations and technology firms:

The digital biomarkers market is expected to show positive growth as a result of numerous collaborations between technology companies and healthcare organizations. Innovative solutions and the successful application of digital biomarkers in healthcare settings are made possible by these collaborations, which combine clinical expertise with technological advancements.

Expansion of Digital Infrastructure and Connectivity:

The expansion of digital infrastructure and connectivity is necessary for the digital biomarkers market to expand. Digital biomarkers can now be seamlessly integrated into healthcare systems owing to the widespread adoption of the internet, advancements in telecommunications, and the introduction of 5G networks. All of these factors have increased access to data collection, storage, and analysis.

North America is anticipated to account for a significant market share.

The North America will hold a considerable market share which is attributable to the region's sophisticated healthcare infrastructure and significant investments in digital health technology. Likewise, the presence of significant pharmaceutical conglomerates and technological giants in the region encourages collaboration and innovation in the development of digital biomarkers. Furthermore, digital biomarkers market growth is fuelled by favorable government initiatives and policies. Lastly, North America's dominance in the digital biomarkers market share is aided by the region's rapid adoption of wearable devices, mobile health applications, and remote patient monitoring solutions.

Key Players in the Digital Biomarkers Market:

Biofourmis: Utilizing wearable technology and artificial intelligence, the comprehensive digital therapeutics platform known as Biofourmis collects and analyses health data generated by patients. For managing chronic conditions and providing post-acute care, some of their options include personalized insights, predictive analytics, and remote monitoring.
Evidation Health: Evidation Health is a company that works on digital biomarker creation and validation by analyzing real-world data from digital devices. The technology they use collects and analyses data from a variety of sources, making it possible to create and evaluate new biomarkers for a wide range of diseases.
Empatica: Smartwatches and wristbands made by Empatica are examples of wearable devices that measure a variety of physiological characteristics. They can find digital biomarkers for conditions like stress and epilepsy thanks to the data they collect from their devices about heart rate, electrodermal activity, and activity levels.

Key Developments:

In March 2023, A new cooperation agreement was announced between Chugai Pharmaceutical Co., Ltd. and Biofourmis, a global leader in technology-enabled care delivery, for ongoing research and the practical application of digital technologies to objectively assess endometriosis patients' pain. 10% of all women of reproductive age are affected by endometriosis, and 70% of those women suffer from chronic pelvic discomfort, affecting their quality of life.
In January 2023, A partnership between the Duke University BIG IDEAs Lab and Evidation was formed to increase diversity and inclusion in digital health research by building an analytic structure that would provide better health analysis in everyday life.

Segmentation

BY TYPE

Mobile Health Apps
Wearable Devices
Others

BY THERAPEUTIC AREA

Cardiovascular Disorders
Neurological Disorders
Respiratory Disorders
Metabolic Disorders
Others

BY END-USER

Pharmaceutical Companies
Healthcare Providers
Research Organizations
Others

BY GEOGRAPHY

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Taiwan
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porter's Five Force Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of New Entrants
- 4.4.4. Threat of Substitutes
- 4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis

5. DIGITAL BIOMARKERS MARKET BY TYPE

5.1. Introduction
5.2. Mobile Health Apps
5.3. Wearable Devices
5.4. Others

6. DIGITAL BIOMARKERS MARKET BY THERAPEUTIC AREA

6.1. Introduction
6.2. Cardiovascular Disorder
6.3. Neurological Disorder
6.4. Respiratory Disorder
6.5. Metabolic Disorder
6.6. Other

7. DIGITAL BIOMARKERS MARKET BY END-USER

7.1. Introduction
7.2. Pharmaceutical Companies
7.3. Healthcare Providers
7.4. Research Organizations
7.5. Others

8. DIGITAL BIOMARKERS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Taiwan
- 8.6.7. Others